Cytokinetics (NASDAQ:CYTK) Price Target Lowered to $80.00 at Royal Bank of Canada
Cytokinetics (NASDAQ:CYTK – Get Free Report) had its price target decreased by Royal Bank of Canada from $82.00 to $80.00 in a report issued on Wednesday,Benzinga reports. The firm presently has an “outperform” rating on the biopharmaceutical company’s stock. Royal Bank of Canada’s price target suggests a potential upside of 146.31% from the stock’s previous […]
Cytokinetics (NASDAQ:CYTK – Get Free Report) had its price target decreased by Royal Bank of Canada from $82.00 to $80.00 in a report issued on Wednesday,Benzinga reports. The firm presently has an “outperform” rating on the biopharmaceutical company’s stock. Royal Bank of Canada’s price target suggests a potential upside of 146.31% from the stock’s previous […]
